Analyzing Auxly Cannabis Group (OTCMKTS:CBWTF) and Protalex (OTCMKTS:PRTX)

Share on StockTwits

Auxly Cannabis Group (OTCMKTS:CBWTF) and Protalex (OTCMKTS:PRTX) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

0.2% of Protalex shares are held by institutional investors. 80.0% of Protalex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Auxly Cannabis Group and Protalex’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auxly Cannabis Group $580,000.00 598.06 -$51.68 million N/A N/A
Protalex N/A N/A -$5.03 million N/A N/A

Protalex has lower revenue, but higher earnings than Auxly Cannabis Group.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Auxly Cannabis Group and Protalex, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxly Cannabis Group 0 0 0 0 N/A
Protalex 0 0 0 0 N/A

Profitability

This table compares Auxly Cannabis Group and Protalex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxly Cannabis Group -652.13% -21.42% -15.06%
Protalex N/A N/A N/A

Risk and Volatility

Auxly Cannabis Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Protalex has a beta of -1.03, suggesting that its share price is 203% less volatile than the S&P 500.

Summary

Protalex beats Auxly Cannabis Group on 6 of the 8 factors compared between the two stocks.

Auxly Cannabis Group Company Profile

Auxly Cannabis Group Inc. operates as a cannabis streaming company. It provides funding for cannabis production; and holds contractual rights and minority equity interest relating to the operation of cannabis facilities. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.

Protalex Company Profile

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

Receive News & Ratings for Auxly Cannabis Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxly Cannabis Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Alphabet Inc  to Post FY2019 Earnings of $48.88 Per Share, Piper Jaffray Companies Forecasts
Alphabet Inc to Post FY2019 Earnings of $48.88 Per Share, Piper Jaffray Companies Forecasts
Analysts Offer Predictions for Cooper Companies Inc’s FY2019 Earnings
Analysts Offer Predictions for Cooper Companies Inc’s FY2019 Earnings
Equities Analysts Offer Predictions for Semafo Inc.’s FY2019 Earnings
Equities Analysts Offer Predictions for Semafo Inc.’s FY2019 Earnings
Piper Jaffray Companies Weighs in on Nio Inc -‘s Q3 2019 Earnings
Piper Jaffray Companies Weighs in on Nio Inc -‘s Q3 2019 Earnings
$1.48 Billion in Sales Expected for KBR, Inc.  This Quarter
$1.48 Billion in Sales Expected for KBR, Inc. This Quarter
Veeco Instruments Inc.  Expected to Announce Quarterly Sales of $109.90 Million
Veeco Instruments Inc. Expected to Announce Quarterly Sales of $109.90 Million


© 2006-2019 Ticker Report